Gold implants and increased expression of metallothionein-I/II as a novel hypothesized therapeutic approach for autism

Toxicology

Volumn 283, Issue 1, 2011, Pages 63-64

  Ghanizadeh, Ahmad ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Inflammation; Metal; Oxidative stress; Treatment

Indexed keywords

CASPASE 3; GOLD; METALLOTHIONEIN I; METALLOTHIONEIN II; REACTIVE OXYGEN METABOLITE; THIOMERSAL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ASTROCYTE; AUTISM; BRAIN NERVE CELL; ENZYME REGULATION; EXCITOTOXICITY; HUMAN; HYPOTHESIS; IMPLANT; LETTER; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AUTISTIC DISORDER; CHILD, PRESCHOOL; DRUG IMPLANTS; GOLD; HUMANS; METALLOTHIONEIN; OXIDATIVE STRESS;

EID: 79953089747     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2011.02.002     Document Type: Letter

References (29)

1. Acarin L., Peluffo H., et al. Astroglial nitration after postnatal excitotoxic damage: correlation with nitric oxide sources, cytoskeletal, apoptotic and antioxidant proteins. J. Neurotrauma 2005, 22(1):189-200.
2. Bay B.H, Jin R., et al. Metallothionein as a prognostic biomarker in breast cancer. Exp. Biol. Med. (Maywood) 2006, 231(9):1516-1521.
3. Blaylock R.L. A possible central mechanism in autism spectrum disorders, part 2: immunoexcitotoxicity. Altern. Ther. Health Med. 2009, 15(1):60-67.
4. Chung R.S, Leung Y.K., et al. Metallothionein treatment attenuates microglial activation and expression of neurotoxic quinolinic acid following traumatic brain injury. Neurotox. Res. 2009, 15(4):381-389.
5. Faber S., Zinn G.M., et al. The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders. Biomarkers 2009, 14(3):171-180.
6. Geier D.A, Kern J.K., et al. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem. Res. 2009, 34(2):386-393.
7. Guzzi G. Of vaccine-autism, thimerosal, and metallothioneins. Pediatr. Allergy Immunol. 2007, 18(1):88. author reply 89.
8. Helal G.K., Aleisa A.M., et al. Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats. Oxid. Med. Cell. Longev. 2009, 2(1):26-35.
9. James S.J, Cutler P., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr. 2004, 80(6):1611-1617.
10. James S.J., Melnyk S., et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2006, 141B(8):947-956.
11. James S.J, Rose S., et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 2009, 23(8):2374-2383.
12. Jin R., Chow V.T., et al. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002, 23(1):81-86.
13. Jin R, Huang J., et al. Clinicopathological significance of metallothioneins in breast cancer. Pathol. Oncol. Res. 2004, 10(2):74-79.
14. Minami T., Miyata E., et al. Induction of metallothionein in mouse cerebellum and cerebrum with low-dose thimerosal injection. Cell Biol. Toxicol. 2011, 26(2):143-152.
15. Pedersen M.O, Jensen R., et al. Metallothionein-I+II in neuroprotection. Biofactors 2009, 35(4):315-325.
16. Pedersen M.O., Larsen A., et al. Bio-released gold ions modulate expression of neuroprotective and hematopoietic factors after brain injury. Brain Res. 2010, 1307:1-13.
17. Penkowa M., Camats J., et al. Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte-targeted interleukin-6 expression. Glia 2003, 42(3):287-306.
18. Russo A.F Anti-metallothionein IgG and levels of metallothionein in autistic families. Swiss Med. Wkly. 2008, 138(5-6):70-77.
19. Sheikh A.M., Li X., et al. Cathepsin D and apoptosis related proteins are elevated in the brain of autistic subjects. Neuroscience 2010, 165(2):363-370.
20. Singh V.K., Hanson J. Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal. Pediatr. Allergy Immunol. 2006, 17(4):291-296.
21. Sogut S, Zoroglu S.S., et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin. Chim. Acta 2003, 331(1-2):111-117.
22. Taylor D.M., Minotti S., et al. Overexpression of metallothionein protects cultured motor neurons against oxidative stress, but not mutant Cu/Zn-superoxide dismutase toxicity. Neurotoxicology 2004, 25(5):779-792.
23. Theoharides T.C, Doyle R., et al. Novel therapeutic targets for autism. Trends Pharmacol. Sci. 2008, 29(8):375-382.
24. Theoharides T.C., Kempuraj D., et al. Autism: an emerging 'neuroimmune disorder in search of therapy. Expert Opin. Pharmacother. 2009, 10(13):2127-2143.
25. Thirumoorthy N., Manisenthil Kumar K.T., et al. Metallothionein: an overview. World J. Gastroenterol. 2007, 13(7):993-996.
26. Villagonzalo K.A., Dodd S., et al. Oxidative pathways as a drug target for the treatment of autism. Expert Opin. Ther. Targets 2010, 14(12):1301-1310.
27. Yu X., Guo J., et al. Basal metallothionein-I/II protects against NMDA-mediated oxidative injury in cortical neuron/astrocyte cultures. Toxicology 2011, 282(1-2):16-22.
28. Zhu J., Meeusen J., et al. Reactivity of Zn-, Cd-, and apo-metallothionein with nitric oxide compounds: in vitro and cellular comparison. Chem. Res. Toxicol. 2010, 23(2):422-431.
29. Zoroglu S.S., Armutcu F., et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254(3):143-147.